To amend subsection (q) of section 505 of the Federal Food, Drug, and Cosmetic Act to clarify the process for denying certain petitions whose primary purpose is to delay the approval of an application submitted under subsection (b)(2) or (j) of such section 505, and for other purposes.

HR8908 was introduced on May 19, 2026, by Rep. Sorensen (D-IL) and referred to the House Committee on Energy and Commerce. It is in the earliest legislative stage with only 3 actions (introduction and referral). The bill amends Section 505(q) of the FD&C Act to clarify that FDA may deny a citizen petition if its primary purpose is to delay approval of a 505(b)(2) or 505(j) application (abbreviated NDAs and certain NDAs referencing prior approvals). This is a procedural clarification, not a substantive change in drug pricing or approval standards. There is no funding authorized or appropriated in this bill. The mechanism is purely regulatory — it tightens FDA's ability to reject dilatory petitions. The obligated party is FDA CDER, which must apply the clarified standard. The direct consequence is a marginal reduction in brand manufacturers' ability to use citizen petitions as a delay tactic for generic entry. However, citizen petitions are a relatively small factor in generic drug delays compared to patent litigation, regulatory exclusivity, and manufacturing challenges. Structural winners are generic drug manufacturers (Teva, Viatris, Sandoz) and companies with strong generic pipelines. However, these companies are not directly named in the bill, and the impact is too diffuse to assign high-confidence causal chains. Brand manufacturers like JNJ and LLY face slightly increased generic competition risk on small-molecule drugs nearing patent expiry, but the effect is marginal given their diversified portfolios and focus on biologics. The bill does not affect biologics (which follow the BPCIA pathway, not 505(j)). No real market data is provided for stock price movements. The legislative timeline is uncertain — the bill has only been referred to committee. It must pass committee, the House, the Senate, and be signed by the President. With a single Democratic sponsor and one cosponsor, passage probability is low in the current Congress. The impact score of 2 reflects the procedural nature, early stage, and narrow scope.